Pfizer Taiwan Recognized with Dual Honors from the “SNQ / National Biotechnology and Medical Care Quality Award” and “National Innovation Award”
Pfizer Taiwan has been recognized with two major innovation and quality accolades, reaffirming the impact of its innovative medicines. In the 2025 evaluations for the SNQ/National Biotechnology and Medical Care Quality Award, as well as the National Innovation Award, three of its products spanning oncology treatment and preventive medicine received top honors, highlighting the company’s excellence in innovative drug development, medical advancement, and product quality.
Pfizer earned SNQ 2025 recognition for three products: a next-generation conjugate vaccine designed to prevent invasive pneumococcal disease, a prefusion antigen-based bivalent vaccine for the prevention of respiratory viral infections, and a therapy for recurrent or refractory multiple myeloma. Among these, the prefusion antigen-based bivalent respiratory vaccine was further awarded the Bronze Prize in the Prescription DrugInternational Pharma category of the National Biotechnology and Medical Care Quality Award, and was the only product recognized in that category. These honors reflect stronga recognition by the judging panel of Pfizer’s high standards in safety, quality, and innovative clinical value.
In addition, at the 22nd National Innovation Award, Pfizer Taiwan was honored for two major respiratory vaccines — the next-generation pneumococcal conjugate vaccine and the prefusion antigen-based bivalent respiratory vaccine — highlighting its progress and breakthroughs in vaccine technology and preventive medicine innovation.
Cellina Yeh, country manager of Pfizer Taiwan, notes that over its 175-year history, Pfizer has continuously advanced pharmaceutical innovation. Since the discovery of penicillin in 1928, which marked the beginning of antibiotic research and helped protect humanity from fatal bacterial threats, the company has continued to shape the global biotechnology and healthcare landscape. By integrating transformative technologies with cutting-edge science, Pfizer has become a pioneer in biopharmaceutical innovation, delivering not only treatments for complex diseases, but also cures and preventive solutions.
Yeh adds that as Taiwan faces rapid population aging alongside declining birth rates, the importance of preventive medicine continues to grow. The design philosophy behind these award-winning products aligns closely with these societal trends, and Pfizer remains committed to advancing vaccine innovation to help build a more resilient public health system in Taiwan.
Beyond preventive medicine, oncology remains a central focus of Pfizer’s innovative drug development. Through advanced clinical trials and precision medicine, the company is delivering breakthrough therapies for breast cancer, lung cancer, hematologic malignancies, and genitourinary cancers — aiming to ensure that more patients can benefit from scientific innovation.
Pfizer is also deeply committed to six core ESG pillars: Climate Change; Product Innovation; Equitable Access & Pricing; Diversity, Equity & Inclusion; Product Quality & Safety; and Business Ethics. Guided by its philosophy of acting with purpose, putting people first, and prioritizing quality, Pfizer continues to harness innovation, quality, and science to strengthen Taiwan’s public health system and support the health of every family.
PP-A1G-TWN-0221-202605
